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Abstract
Background: Depression has serious personal, family and economic consequences. It is estimated that it will cost
£12.15 billion to the economy each year in England by 2026. Improving access to psychological therapies (IAPT) is
the National Health Service talking therapies service in England for adults experiencing anxiety or depression. Over
1 million people are referred to IAPT every year, over half experiencing depression. Where symptoms of depression
are mild to moderate, people are typically offered cognitive behavioural therapy (CBT) self-help (CBT-SH) supported
by a psychological well-being practitioner. The problem is that over half of people who complete treatment for
depression in IAPT remain depressed despite receiving National Institute of Health and Care Excellent
recommended treatment. Furthermore, less than half of IAPT service users complete treatment. This study seeks to
investigate the effectiveness of an alternative to CBT-SH. Mindfulness-based cognitive therapy (MBCT) differs from
CBT in focus, approach and practice, and may be more effective with a higher number of treatment completions.
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Methods/design: This is a definitive randomised controlled trial comparing supported MBCT self-help (MBCT-SH)
with CBT-SH for adults experiencing mild to moderate depression being treated in IAPT services. We will recruit 410
participants experiencing mild to moderate depression from IAPT services and randomise these to receive either an
MBCT-based self-help workbook or a CBT-based self-help workbook. Participants will be asked to complete their
workbook within 16 weeks, with six support sessions with a psychological well-being practitioner. The primary
outcome is depression symptom severity on treatment completion. Secondary outcomes are treatment completion
rates and measures of generalized anxiety, well-being, functioning and mindfulness. An exploratory non-inferiority
analysis will be conducted in the event the primary hypothesis is not supported. A semi-structured interview with
participants will guide understanding of change processes.
Discussion: If the findings from this randomised controlled trial demonstrate that MBCT-SH is more effective than
CBT-SH for adults experiencing depression, this will provide evidence for policy makers and lead to changes to
clinical practice in IAPT services, leading to greater choice of self-help treatment options and better outcomes for
service users. If the exploratory non-inferiority analysis is conducted and this indicates non-inferiority of MBCT-SH in
comparison to CBT-SH this will also be of interest to policy makers when seeking to increase service user choice of
self-help treatment options for depression.
Trial registration: Current Controlled Trial registration number: ISRCTN 13495752. Registered on 31 August 2017
(www.isrctn.com/ISRCTN13495752).
Keywords: Depression, Mindfulness, Cognitive behavioural therapy, CBT, Mindfulness-based cognitive therapy,
MBCT, Self-help, Randomised controlled trial, RCT
Background
Around 15% of adults in England experience clinically
significant depression or anxiety in any week [1]. Im-
proving access to psychological therapies (IAPT) is an
initiative launched by the National Health Service (NHS)
in England in 2006 that aims to improve access to psy-
chological therapies for people experiencing anxiety and
depression, with over 1.5 million people now referred to
IAPT each year [2].
Depression is typically recurrent; following one epi-
sode of major depression, 50% will relapse, and after two
episodes 80% relapse [3]. In addition to the impact on
individuals and their families, depression is estimated to
cost the economy in England £12.15 billion a year by
2026 [4]. In order to meet the needs of people experien-
cing depression, IAPT typically offers stepped-care [5]
consisting of supported self-help at ‘step 2’ followed by,
where needed, face-to-face therapy at ‘step 3’. In line
with National Institute of Health and Care Excellence
(NICE) guidelines [6], at step 2 people are provided with
cognitive behavioural therapy (CBT) self-help (CBT-SH)
materials supported by a trained psychological well-
being practitioner (PWP).
However, IAPT has shown modest treatment out-
comes for CBT-SH; only 41% of people receiving book-
based PWP-supported CBT-SH for depression met cri-
teria for remission in the 2018–2019 financial year [2].
In addition, this figure is for initial remission and does
not consider sustained recovery [7]. Partial remission
from depression is associated with a greater risk of re-
lapse [8]. A related problem in IAPT is high rates of
treatment drop-out; only 36% of people referred to IAPT
in 2018–2019 completed a course of treatment [2].
Completing treatment is important because it is associ-
ated with better outcomes [9]. Moreover, costs for treat-
ment non-completers surpass that of treatment
completers in IAPT [10]. However, there is poor under-
standing of the reasons for non-completion [11], and
this evidence gap needs addressing. Improving remission
rates for depression and increasing treatment comple-
tion require urgent attention.
Mindfulness is the capacity to pay attention,
intentionally and non-judgmentally, to current experi-
ence. Mindfulness-based interventions (MBIs) teach the
application of mindfulness in everyday life and work by
reducing rumination and worry [12]. They address well-
established mechanisms which trigger and maintain de-
pression [13]. MBIs differ from CBT in important ways:
1) CBT includes evaluating the accuracy of difficult
thoughts, whereas MBIs encourage a self-compassionate,
non-judgmental and accepting attitude towards experi-
ence, including unpleasant thoughts; 2) regular medita-
tion practice (verbally guided attention towards present
moment experiences) is integral to MBIs but is not in-
cluded in CBT (meditation is the training ground that
enables participants to experience thoughts in the mo-
ment as transient mental events [14]); and 3) participant
experience is different in terms of content and goals.
Mindfulness-based cognitive therapy (MBCT) is a
group therapy recommended for relapse prevention for
depression in the UK by NICE [15] that includes ele-
ments of CBT for depression. Meta-analyses show that
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MBCT reduces the relative risk of relapse for people
with a history of multiple episodes of depression by 31%
[16]. Mindfulness-based group interventions, in com-
parison to control conditions, lead to significant reduc-
tions in depression severity for people currently
depressed [17]. Thus, MBCT groups are a good candi-
date for not only attaining initial symptom remission but
also for achieving sustained recovery and preventing re-
lapse. However, this evidence applies to formal face-to-
face MBCT groups, delivered by highly trained MBCT
therapists, and we cannot assume this potential will gen-
eralise to a supported self-help intervention in a service
such as IAPT.
MBCT self-help (MBCT-SH) delivered at step 2 in
IAPT services has the potential to reduce the cost of de-
livery and to widen access to people unable or unwilling
to attend a group [18]. This protocol is for a definitive
randomised controlled trial of clinical and cost effective-
ness comparing MBCT-SH with CBT-SH for people ex-
periencing mild to moderate depression. Our primary
hypothesis is that supported MBCT-SH, in comparison
to supported CBT-SH, will lead to greater reductions in
depressive symptom severity from baseline to post-
intervention.
Secondary hypotheses are:
 MBCT-SH in comparison to CBT-SH will lead to
greater reduction in depressive symptom severity
from baseline to 6-month follow-up.
 A greater proportion of MBCT-SH participants will
be in the non-clinical range for depressive symptoms
than CBT-SH participants at post-intervention (i.e.
remission) and 6-month follow-up (i.e. recovery).
 MBCT-SH in comparison to CBT-SH will lead to
greater improvements in mindfulness, generalised
anxiety, work and social adjustment and well-being
from baseline to post-intervention and from baseline
to 6-month follow-up.
 Treatment completion rates will be higher for
MBCT-SH than CBT-SH.
 Depressive symptom severity outcomes will be
mediated by treatment completion.
 MBCT-SH will be cost-effective in comparison to
CBT-SH at follow-up.
 MBCT-SH will be a safe alternative to CBT-SH,
with a similarly low incidence of serious adverse
events during therapy and lasting negative effects of
therapy.
In the event that the primary hypothesis of MBCT-SH
superiority over CBT-SH on the primary outcome is not
supported an additional exploratory analysis will be car-
ried out to explore non-inferiority of MBCT-SH com-
pared to CBT-SH.
A qualitative component will close the evidence gap
concerning reasons for treatment non-completion in
IAPT services by identifying facilitators and barriers to
treatment completion in both arms. Qualitative inter-
views will be conducted using the Change Interview [19]
to ascertain facilitators and barriers to treatment com-
pletion for each intervention. Questions were added to
the end of interview following advice from the study’s
lived experience public and patient involvement (PPI)
consultation panel. These questions enquire about par-
ticipants’ experiences of their allocated intervention be-
yond depressive symptom change.
Methods/design
Design and sample size
This is a parallel-group, superiority, pragmatic, rando-
mised controlled trial with 1:1 allocation to MBCT-SH
or CBT-SH, with blinded assessments at all time points.
Participants will be blind to the hypothesised direction
of effects. We will randomly allocate 410 people meeting
eligibility criteria for major depressive disorder or mixed
anxiety and depression to receive MBCT-SH or CBT-
SH, along with six sessions of support from a PWP. Par-
ticipants will complete measures at baseline (time 0), 16
weeks post-randomisation (post-intervention, time 1)
and 42 weeks post-randomisation (6-month follow-up,
time 2). In addition, 24 participants will be interviewed
about their experiences of both self-help interventions
(12 participants per arm) at time 1 with a focus on bet-
ter understanding barriers and facilitators to engaging in
self-help interventions in IAPT services and investigating
any negative experiences or effects of treatments.
The sample size was based on detecting a between-group
effect size of 0.36 based on the difference between the re-
ported between-group effect of CBT-SH (0.42) [20] and the
reported between-group effect of MBCT-SH (0.78) [21].
Recruiting 205 patients into each arm would provide 90%
power to detect a between-group difference of 0.36 with a
5% alpha and a two-sided t test whilst allowing for 20% at-
trition at post-intervention (as found in our pilot study).
Therefore, a total sample size of 410 will be required.
The study design was informed through consultation
with a PPI group chaired by a PPI co-applicant consultant
(LL). Members of the PPI group had participated in a pilot
study of the intervention or had lived experience of de-
pression, mindfulness and/or CBT. The PPI group were
instrumental in advising on a number of aspects of study
design including the frequency and nature of support ses-
sions and the study recruitment strategy and materials.
Participants
Participants will be recruited through ten IAPT services
across England. A list of sites can be requested through
the corresponding author.
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Inclusion criteria are that participants: 1) be aged 18
years or over; 2) meet diagnostic criteria on the revised
Clinical Interview Schedule (CIS-R) [22] for a primary
diagnosis of a depressive episode, mixed anxiety and de-
pression, or non-specified mild neurotic disorder; 3)
score 10 or more on the Patient Health Questionnaire 9
(PHQ-9) [23] at their initial IAPT assessment (cut-off in-
dicating a probable major depressive episode); and 4)
have sufficient literacy skills to read and understand the
self-help materials.
Exclusion criteria are that participants: 1) have severe
symptoms of depression (a score 20 or more on the
PHQ-9); 2) a score of 4 on the CIS-R suicidality scale;
and 3) express a strong preference (5/5) for one inter-
vention over the other on the treatment preference
question such that if randomised to the non-preferred
intervention they would be likely to drop out of the
intervention.
Measures
Demographics
A questionnaire will be completed to collect demo-
graphic information.
Diagnostic status
The CIS-R [22] will be conducted at baseline (time 0) to
ascertain diagnostic status. The CIS-R is routinely used
in primary care mental health and IAPT research [1]
and has been validated for telephone completion [24].
Primary outcome measure
Depression symptom severity will be measured using the
PHQ-9 [23], a nine-item self-report measure of depres-
sion symptom severity used in all IAPT services with
good sensitivity and specificity. Items are rated on a
four-point scale. Scores under 10 are considered sub-
clinical, 10–14 mild, 15–19 moderate and 20+ severe.
The PHQ-9 will be administered at time 0, time 1 and
time 2.
Secondary outcome measures
Generalised anxiety will be measured with the General-
ised Anxiety Disorder 7 [25], a seven-item measure of
generalised anxiety used in IAPT. Items are rated on a
four-point scale and the measure has excellent psycho-
metric properties [25]. This will be administered at time
0, time 1 and time 2.
Well-being will be measured with the short version of
the Warwick Edinburgh Mental Well-being Scale [26],
which consists of seven questions rated on a five-point
scale designed to measure well-being. The scale has
good psychometric properties and is used widely [27].
This measure was added following advice from the PPI
consultation panel. This will be administered at time 0,
time 1 and time 2.
Functioning will be measured with the Work and So-
cial Adjustment Scale [28], a five-item measure of daily
occupational and social functioning that is used rou-
tinely in IAPT. This will be administered at time 0, time
1 and time 2.
Mindfulness will be measured using the 15-item ver-
sion of the Five-Facet Mindfulness Questionnaire [29].
This has excellent psychometric properties and is sensi-
tive to change following MBCT [29]. This will be admin-
istered at time 0, time 1 and time 2.
The Change Interview [19] will be used to guide the
qualitative component of the study. This is a widely
used, semi-structured interview designed to explore par-
ticipants’ experiences of psychological interventions and
has been successfully used in previous studies by members
our team. Questions about participants’ experiences of the
effects of their allocated intervention on personally rele-
vant outcomes (i.e. not necessarily restricted to depressive
symptoms) have been added at the end of the interview
following advice from the study’s lived experience consult-
ation panel. The Change Interview will be conducted by
the PPI consultant co-applicant on the study (LL) with the
expectation that this will facilitate participants to be open
about their experiences of the study and interventions.
This will be conducted at time 1.
Health economic measures
For service use, an adapted version of the Adult Service
Use Schedule (AD-SUS) will be used to measure
individual-level all-cause hospital and community-based
health and social care resource use. The AD-SUS was
developed in previous research for use with people with
common mental disorders [30, 31] and has been adapted
for the purposes of this study. The baseline (time 0) AD-
SUS will cover the period 3 months prior to randomisa-
tion. At the time 1 and time 2 follow-up interviews, the
AD-SUS will cover the period since the last interview.
For health-related quality of life we will use the five-
level version of the EuroQol five dimension (EQ-5D-5L)
[32] generic, preference-based measure of health-related
quality of life covering mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. We will use the
recently developed five level version to maximise sensi-
tivity [33]. This measure will be administered at time 0,
time 1 and time 2.
Intervention evaluation measures and tools
The intervention expectation form will be used to assess
expectation of benefit and treatment credibility at time 0.
The lasting negative effects questionnaire will be used
to ask participants about any lasting negative effects of
their allocated intervention at time 2.
Strauss et al. Trials          (2020) 21:374 Page 4 of 10
The PWP rating scale will be used for participants to
rate the quality/helpfulness of the sessions between the
participant and their PWP at time 1.
Weekly diaries will record the extent to which partici-
pants are engaging with the self-help course each week
during intervention delivery.
The engagement questionnaire (at the end of treat-
ment) will record the extent to which participants en-
gaged with the self-help course during the entire course
of the intervention and will be administered at time 1.
The engagement questionnaire (at follow-up) will rec-
ord the extent to which participants continued to engage
with the self-help course following the end of the inter-
vention and will be administered at time 2.
Session attendance will be the number of PWP ses-
sions attended (0–6) and the duration of each support
session.
Treatment completion is defined as attending at least
50% of the PWP sessions (i.e. attending at least three
sessions).
Procedure
See Fig. 1 for the SPIRIT schedule of enrolment, inter-
ventions and assessments. Patients with a diagnosis of
depression will be sought through IAPT services. The
study will also be advertised in general practitioner sur-
geries and elsewhere. Self-referrers will be guided to the
study via their local IAPT service. Informed consent will
be obtained from each participant. Potential participants
will be given a copy of the study participant information
sheet and will have the opportunity to discuss the study
in person with the research assistant (RA) before signing
the consent form (a copy of which can be obtained from
the corresponding author).
Once the participant has consented to participate in
the trial, the participant will complete the full set of
baseline measures with an RA present in person or by
telephone. Measures will be completed online or on
paper, depending on participant preference. Participants
who do not meet eligibility criteria at the baseline assess-
ment will be referred back to the person who conducted
their initial assessment for usual care to be offered by
the service.
At the end of the baseline assessment, eligible partici-
pants will be randomised to either the MBCT-SH or
CBT-SH arm. Participants will then be given their allo-
cated self-help workbook. Randomisation will be strati-
fied by centre and PHQ-9 score (mild or moderate)
using random block length. Eligible participants will be
randomly allocated using the Sealed Envelope [34] on-
line service. The study statistician will use Sealed Enve-
lope to set up and test the randomisation procedure,
incorporating stratification by site and PHQ-9 severity
category (mild or moderate) using random block length
and 1:1 allocation. The statistician will not have any fur-
ther involvement in the randomisation process. The RA
will randomise participants by completing the online
form with participant’s details. This will immediately
Fig. 1 Schedule of enrolment, interventions, and assessments. CBT-SH cognitive behavioural therapy self-help, MBCT-SH mindfulness-based
cognitive therapy self-help
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show whether the participant is assigned to the MBCT-
SH or CBT-SH arm and participants will be given their
self-help workbook. Participants will not be told the hy-
potheses in relation to the arm to which they have been
randomised.
Participants will then guide themselves through their
allocated intervention over the 8-week course with six
PWP support sessions. A maximum of 16 weeks is given
for the intervention period to allow participants to
complete their allocated 8-week course to take account
of breaks for holidays, sickness and so forth. PWP sup-
port sessions may be offered by telephone or face-to-
face, depending on usual practice in the service and par-
ticipant preference. This mirrors the usual way in which
self-help interventions are offered in IAPT (i.e. offering a
self-help workbook alongside a limited number of PWP
support sessions).
Participants will complete measures online (with a
postal option) at 16 weeks post-randomisation (post-
intervention, time 1) and 42 weeks post-randomisation
(6-month follow-up, time 2). Participants will have the
option to choose whether to complete the time 1 and
time 2 measures with an RA present in person or by
telephone (who will be blind to group allocation) or on
their own. In the event that an RA is required to be
present during time 1 or time 2 assessments and be-
comes unblinded the assessment will be completed by
another, blinded RA. Where time 1 and time 2 assess-
ments are not completed, participants will be contacted
at weekly intervals for up to 1 month to remind them to
complete these assessments, unless participants have dis-
continued from the study.
Twenty-four participants will be invited to take part in
the qualitative Change Interview after their post-
intervention (time 1) quantitative assessment is com-
pleted. Participants will be interviewed on a first-come,
first-served basis, with 12 participants interviewed in
each of two groups: 1) MBCT-SH intervention com-
pleters; and 2) CBT-SH intervention completers.
Therapy protocols
MBCT-SH
The MBCT-SH workbook ‘The Mindful Way Work-
book’ [35], written for clinical populations, presents
MBCT as a self-help package. MBCT-SH participants
will be given the workbook and will be asked to guide
themselves through the self-help course within a 16-
week time period (the time period determined in our
pilot). As is routine at step 2, participants will be offered
six PWP sessions to answer questions and provide
encouragement.
PWPs currently train in CBT-SH. To match training
between arms we will offer PWPs training in MBCT-SH.
The training involves PWPs: 1) attending an MBCT
group as a participant and guiding themselves through
the MBCT-SH workbook, or completing the MBCT
course using the workbook as a guide; and 2) attending
a 2-day experiential mindfulness skills workshop. As is
standard in delivering MBIs, PWPs will be encouraged
to maintain their own personal mindfulness practice
throughout the study, and this will be recorded using
the PWP mindfulness practice record. Fortnightly
MBCT-SH group supervision for PWPs will be provided.
CBT-SH
The CBT-SH workbook ‘Overcoming Low Mood and
Depression’ [36] has evidence demonstrating its effect-
iveness in reducing depression symptom severity [37].
This workbook is often used at step 2 in IAPT.
Matched to the MBCT-SH condition, participants allo-
cated to CBT-SH will be given a copy of their workbook
and will be encouraged to guide themselves through the
workbook within 16 weeks alongside six PWP sessions
to answer questions and provide encouragement.
As in the MBCT-SH condition, fortnightly CBT-SH
group supervision for PWPs will be provided.
Intervention fidelity and adherence
The same PWPs will deliver both interventions in order
to minimise therapist effects as some PWPs achieve sub-
stantially better outcomes than others. In order to min-
imise therapeutic drift and therapy contamination the
PWP protocols are detailed and there will be fortnightly
supervision of PWPs. PWPs will be asked to audio rec-
ord at least one complete MBCT-SH case and at least
one complete CBT-SH case. A random 10% sample of
recordings from each PWP will be rated for fidelity to
the therapy protocols by a clinical psychologist trained
in CBT and MBCT and who is independent of the PWP
training and supervision.
Participants will be prompted each week by the RA to
complete weekly diaries (online/paper versions) to rec-
ord the amount of the workbook read and time spent
engaged in intervention tasks.
Serious adverse event monitoring
A protocol for identifying and independently assessing
serious adverse events will ensure that such events are
addressed in a timely fashion and responded to, includ-
ing if a serious adverse event is classified as potentially
study-related. Serious adverse events and their classifica-
tion will be reported to the Data Safety Monitoring
Board (DSMB) and Trial Steering Committee (TSC) and
action will be taken as deemed necessary.
Serious and other adverse events will be discussed in
intervention supervision (with CS or FJ) and in service-
based clinical supervision in the relevant IAPT service.
Where deemed in the best interests of participants, the
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study intervention may be discontinued and other treat-
ment options may be recommended by the IAPT
service.
Planned data analysis
The primary analysis will be a quantitative analysis of
the primary outcome at the primary end point (time 1)
using an intention-to-treat (ITT) approach where partic-
ipants are analysed as per their randomisation allocation
regardless of treatment received.
Secondary analyses will consist of ITT analyses of the
primary outcome at the follow-up time point (time 2)
and all secondary outcomes. A per-protocol analysis will
also be carried out for those participants receiving an
adequate dose of their allocated intervention, defined as
attending at least 50% of the PWP sessions (i.e. at least
three sessions).
A descriptive summary of all measures will be pro-
vided by group (MBCT-SH and CBT-SH) and time point
(time 0, time 1 and time 2) as appropriate. Comparisons
between groups for all measures will be carried out
using independent t tests and Chi-square testing for
continuous and categorical data, respectively. Unstandar-
dised effect sizes for the primary outcome and secondary
outcomes will be estimated using linear mixed models
with treatment group (MBCT-SH versus CBT-SH), time
and a treatment group by time interaction entered as
fixed factors; site, baseline PHQ-9 and baseline value of
the outcome will be entered as covariates. Individual
participants will be included in the analysis as random
effects. Contrasts will be used as appropriate to estimate
effects at different time points. A non-significant group
by time interaction will imply common treatment effects
at each time point.
Standardised (Cohen’s d) effect sizes for each outcome
will be calculated by dividing the between-group unstan-
dardized effect by the baseline pooled standard devi-
ation. In addition, 95% confidence intervals will be
calculated for all unstandardised estimates. Group differ-
ences in dichotomous outcomes at the different time
points will be analysed in a similar way but using multi-
level logistic regression models and baseline PHQ-9
scores. Baseline balance will be presented in the descrip-
tive table broken down by study arm. No adjustment will
be made for differences between covariates at baseline.
Outliers will be removed if, and only if, they look erro-
neous. Scores at the extreme will not be removed if they
are deemed to be true. The suitability of the assumption
of approximate normality will be explored by plotting
the residuals from this model. If normality is violated
then transformations and non-parametric testing will be
employed. A sensitivity analysis will be performed by
carrying out the final analysis on the primary outcome,
with and without any individual cases that were involved
in violations of the protocol.
Additional exploratory analysis
In the event that there is no evidence to support the pri-
mary hypothesis of MBCT-SH superiority over CBT-SH
on our primary outcome, an additional exploratory ana-
lysis will be carried out to explore non-inferiority of
MBCT-SH compared to CBT-SH. The analysis will be
based on detecting a between-group non-inferiority mar-
gin of 2 points on the PHQ-9 with a one-sided α = 0.025.
To operationalise this, a two-sided 95% confidence inter-
val will be created around the effect size (MBCT-SH −
CBT-SH) and we will conclude non-inferiority if the
upper limit of the confidence interval is wholly below 2
PHQ-9 points for both the per-protocol and ITT ana-
lyses. The non-inferiority limit was set through consult-
ation with service users and clinicians and looking at the
literature [38, 39].
Data entry accuracy and missing data
We aim to minimise missing data and data entry inac-
curacies at the point of collection. The Qualtrics online
survey software used to collect all data will automatically
flag any unanswered questions, giving participants the
chance to answer these. If a participant would prefer not
to answer a question they can leave it unanswered for a
second time and the software will proceed onto the next
page. At the point of analysis, data will be summarised
to look at patterns of missingness. Missing data will be
replaced using multiple imputation as appropriate. Miss-
ing data will be assessed and if more than 5% of data is
missing multiple imputation will be carried out followed
by a sensitivity analysis. The sensitivity analysis will
compare the results for a complete case analysis to the
imputed data analysis. Multiple imputation will be car-
ried out under the assumption the data is missing at ran-
dom. Anonymised data will be stored on the Qualtrics
platform and on password-protected NHS and university
computers. Personal data will be stored securely in
locked filing cabinets in NHS research offices and on
password-protected NHS computers.
Planned interim analysis and stopping rules
No interim analysis has been planned. The trial will be
paused or stopped if deemed necessary by the DSMB.
Multiple testing
There shall be no multiple testing.
Economic evaluation
The economic evaluation will be conducted covering the
period from time 0 to time 2 and will take the NHS/per-
sonal social services perspective preferred by NICE [40].
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Data on resource use from the AD-SUS will be com-
bined with unit costs to calculate the total costs of the
MBCT-SH and CBT-SH groups. The cost of the two in-
terventions, MBCT-SH and CBT-SH, will be calculated
using a micro-costing approach [41] based on the salary
of the PWPs, including relevant on-costs and overheads.
Data on the number and duration of PWP contacts in
the MBCT-SH and CBT-SH arms will be recorded using
a proforma completed by PWPs. Data on indirect time,
including preparation and supervision, will be collected
directly from the PWPs. All other health and social care
services will be costed using nationally applicable pub-
lished unit costs, such as the NHS reference costs for
hospital costs, the British National Formulary for medi-
cation and the Personal Social Services Research Unit
costs of health and social care.
Costs and outcomes will be compared and presented
in terms of mean differences and 95% confidence inter-
vals obtained by non-parametric bootstrap regression to
account for the non-normal distribution commonly
found in economic data [42]. Cost effectiveness will be
assessed through the calculation of incremental cost-
effectiveness ratios and will be explored in terms of
quality-adjusted life years calculated from the EQ-5D-5L
and using the area under the curve approach [43]. Un-
certainty will be explored using cost-effectiveness planes
and cost-effectiveness acceptability curves based on the
net-benefit approach [44, 45]. These curves are an alter-
native to confidence intervals around incremental cost-
effectiveness ratios and show the probability that one
intervention is cost effective compared to the other for a
range of values that a decision maker would be willing
to pay for an additional unit of an outcome. All eco-
nomic analyses will include relevant baseline variables to
provide a more relevant treatment-effect estimate [46].
The primary analysis will include those with complete
data needed to be included in the economic evaluation.
Sensitivity analyses will explore the impact of missing
data.
Qualitative data analysis
Qualitative data will be analysed using thematic analysis
[47] to identify facilitators and barriers to treatment
completion for each intervention arm. Analysis will be
informed by the structure of the Change Interview [19],
but it will also be able to identify inductively derived
themes reflecting participants’ experiences.
Discussion
CBT-SH, supported by a PWP, is the usual treatment of-
fered in IAPT services to people with mild to moderate
symptoms of depression. However, over half of people
who complete this treatment remain depressed and, fur-
thermore, less than half of IAPT service users complete
treatment. This results in disappointing treatment out-
comes for many service users and increasing costs for
mental health services in primary care. Finding an alter-
native, more effective self-help treatment would lead to
better outcomes for service users and a more efficient
use of NHS resources.
MBCT-SH differs from CBT-SH in focus, approach
and practice, but it may still be able to be delivered in
IAPT services with support from PWPs. By teaching ser-
vice users the ability to intentionally pay attention, non-
judgementally, to current experience, MBIs aim to re-
duce rumination and worry, key components of depres-
sion, by teaching the application of mindfulness in
everyday life and work. MBCT-SH, therefore, offers a
potentially viable and more effective alternative to CBT-
SH for improving both outcomes for service users and
treatment completion rates.
This definitive randomised controlled trial directly
compares MBCT-SH to CBT-SH with the primary aim
of determining the clinical and cost effectiveness of
MBCT-SH at reducing depression symptom severity
compared to CBT-SH. There is also much less known
about the effectiveness of supported self-help
mindfulness-based interventions in comparison to their
in-person group-based counterparts and so this trial will
advance understanding in this area. If the primary super-
iority hypothesis is not supported, the exploratory non-
inferiority analysis will help elucidate if MBCT-SH may
be non-inferior to current best practice (i.e. CBT-SH)
and therefore findings will be of clinical relevance. Find-
ings from the Change Interview will highlight facilitators
and barriers to engagement in both MBCT-SH and
CBT-SH and will hopefully lead to recommendations for
maximising engagement to both these interventions.
The results of this trial will provide valuable evidence
to inform clinical practice and commissioners of ser-
vices. This could enable a greater choice in effective
treatment options for IAPT service users, help elucidate
issues around why some people are unable to complete
treatment and allow for a more efficient use of NHS re-
sources. The results will also provide evidence more
generally about mindfulness-based interventions, their
clinical and cost effectiveness, and the mechanisms of
change which underpin them.
Trial status
At the time of manuscript submission, recruitment for
this study was ongoing. Recruitment started on 6 No-
vember 2017 and is due to be completed on 31 January
2020. The first patient was randomised on 24 November
2017. This is protocol version 1 (18 January 2020). The
trial sponsor is the Sussex Partnership NHS Foundation
Trust (ResearchGovernance@sussexpartnership.nhs.uk).
Strauss et al. Trials          (2020) 21:374 Page 8 of 10
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04322-1.
Additional file 1. SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents.
Abbreviations
AD-SUS: Adult Service Use Schedule; CBT: Cognitive Behavioural Therapy;
CBT-SH: Cognitive behavioural therapy self-help; CIS-R: Revised Clinical
Interview Schedule; DSMB: Data Safety Monitoring Board; EQ-5D-5L: Five-
level, five-dimension EuroQol measure; IAPT: Improving access to
psychological therapies; ITT: Intention-to-treat; MBCT: Mindfulness-based
cognitive therapy; MBCT-SH: Mindfulness-based cognitive therapy self-help;
MBI: Mindfulness-based intervention; NHS: National Health Service;
NICE: National Institute of Health and Care Excellence; PHQ-9: Patient Health
Questionnaire 9; PPI: Public and patient involvement; PWP: Psychological
well-being practitioner; RA: Research assistant; TSC: Trial Steering Committee
Acknowledgements
We would like to thank the RfPB stream of NIHR for funding this study (PB-
PG-0815-20056) and we would like to thank Brighton & Sussex Clinical Trials
Unit for supporting delivery of the study. This study would not be possible
without the hard work and dedication of the study RAs and we are very
grateful to them: E. Ball, P. Beadle, C. Burke, M. Christoforou, R. Denny, G.
Emery, N. Fagbemi, L. Groom, M. Heeger, M. Karanasiou and A. Pound. We
would like to thank the IAPT services for agreeing to take part in this study,
the Principal Investigators (PIs) and clinical leads in these sites and the PWPs
agreeing to contribute their time to the study. The IAPT services are:
Brighton and Hove Well-being Service (PI: J. Couche, step 2 lead: L. Gray),
East Riding Emotional Well-being Service (PI and step 2 link: Z. Lane), Health
in Mind in East Sussex (PI: J. Couche, step 2 lead, J. Shepherd), Health in Mind
in North-East Essex (PI: M. Rosairo, step 2 lead: J. Birsall), italk in Hampshire,
Lewisham IAPT service (PI: J. Wingrove and K. Rimes, step 2 lead: J. Ganley),
South West Yorkshire Partnership NHS Foundation Trust (PI: R. Stebbings),
Talking Change in Portsmouth (PI: M. Ghomi, step 2 lead: C. Hodges), Talking
Therapies Southwark (PI: J. Wingrove and K. Rimes, step 2 lead: J. Wingrove)
and Time to Talk in West Sussex (PI: C. Taylor, service leads: S. Winter and S.
Cullen). We are extremely grateful to members of the PPI group who con-
tributed to the design, who will support delivery of the study, and who will
contribute to dissemination of findings.
Confidentiality
Participants will be assigned a unique identification code which will be used
to complete assessments and will be used for data files.
Trial oversight
Brighton & Sussex Clinical Trials Unit will help to manage the study. The TSC
will compromise an independent chair, two additional independent
members and two lay members. The chief investigator (CS), trial manager
(AA) and trial statistician (A-MJ) will also attend the TSC meetings. The role of
the TSC will be to oversee the trial and ensure that it is running in line with
the HRA-approved protocol. The DSMB will compromise an independent
chair and two additional independent members, and will be of separate
membership to the TSC. The DSMB will be independent of the study spon-
sor. The chief investigator (CS), trial manager (AA) and trial statistician (A-MJ)
will also attend the DSMB meetings when requested to do so by the chair.
The DSMB will have oversight of study data and will have the authority to
pause or close the trial if it has concerns about participant safety or trial in-
tegrity. TSC reports will be shared with members of the DSMB and vice versa.
Copies of the DSMB and TSC charters can be requested from the corre-
sponding author. A Lived Experience Advisory Panel will comprise of PPI
members and will be chaired by the study PPI consultant and co-applicant
(LL). The Lived Experience Advisory Panel will meet on seven occasions dur-
ing the course of the study and their role will be to advise on recruitment
and retention strategies and participant experience, and they will contribute
to dissemination of study findings to participants, patients and the public.
The PPI consultant on the study (LL) will attend weekly operational meetings
to oversee the day-to-day running of the study from a PPI perspective and
to act as bridge between the research team and the Lived Experience Advis-
ory Panel.
Dissemination
Findings will be written up regardless of outcome for publication in peer-
reviewed journals, and an accessible summary of findings will be produced
for participants and members of the public with the support of the Lived Ex-
perience Advisory Forum.
Authors’ contributions
CS led on study design with all authors contributing to the design of the
study. CS and CR wrote the first draft of the manuscript with all authors
contributing to subsequent drafts. All authors read and approved the final
manuscript.
Funding
This paper presents independent research funded by the National Institute
for Health Research (NIHR) under its Research for Patient Benefit (RfPB)
Programme (grant reference number PB-PG-0815-20056). Data collection,
data storage, data analysis, interpretation of findings and the decision to
publish findings will be conducted independently of the funders. The views
expressed are those of the authors and not necessarily those of the NIHR or
the Department of Health and Social Care.
Availability of data and materials
The datasets created for the current study will be available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
This study has received full ethical approval from the Health Research
Authority (HRA) in the UK (Research Ethics Committee reference: 17/LO/
0596). Informed consent will be obtained from all participants through
completion of a consent form. Important modifications to the trial protocol
will be submitted for approval from the trial sponsor and HRA.
Consent for publication
Participants will be asked to consent to their anonymised data being used in
research publications.
Competing interests
CS is research lead for the Sussex Mindfulness Centre and has received NIHR
and other funding for research trials evaluating mindfulness-based interven-
tions. KC, FJ, LL, CR and SB have received research funding to evaluate
mindfulness-based interventions. All remaining authors declare that they
have no competing interests.
Author details
1School of Psychology, University of Sussex, Pevensey Building, Falmer BN1
9QH, UK. 2Sussex Partnership NHS Foundation Trust, R&D Department, Sussex
Education Centre, Nevill Avenue, Hove BN3 7HZ, UK. 3Brighton and Sussex
University Hospitals NHS Trust, Royal Sussex County Hospital, Eastern Road,
Brighton BN2 5BE, UK. 4Brighton & Sussex Clinical Trials Unit, Bevendean
House, University of Brighton, Falmer BN1 9PH, UK. 5Clinical Psychology Unit,
Department of Psychology, University of Sheffield, S10 2TP, Sheffield, UK.
6King’s Health Economics Research Group and Health Service and Population
Research Department, Institute of Psychiatry, Psychology & Neuroscience,
King’s College London, London SE5 8AF, UK. 7Centre for Mindfulness
Research and Practice, School of Psychology, Bangor University, Bangor,
Gwynedd LL57 2AS, UK. 8School of Health Sciences, University of Brighton,
Village Way, Brighton BN1 9PH, UK. 9Canterbury Christ Church University,
Salmons Institute for Applied Psychology, Lucy Fildes Building, 1 Meadow
Road, Tunbridge Wells TN1 2YG, UK. 10School of Health and Related
Research, University of Sheffield, S10 2TP, Sheffield, UK.
Received: 31 January 2020 Accepted: 10 April 2020
References
1. McManus S, Meltzer H, Brugha TT, Bebbington PP, Jenkins R. Adult
psychiatric morbidity in England, 2007 results of a household survey.
London: NHS Information Centre for Health and Social Care; 2009.
Strauss et al. Trials          (2020) 21:374 Page 9 of 10
2. Health and Social Care Information Centre (HSCIC). Psychological therapies,
annual report on the use of IAPT services 2018–19. 2019. Available from: https://
digital.nhs.uk/data-and-information/publications/statistical/psychological-
therapies-annual-reports-on-the-use-of-iapt-services/annual-report-2018-19.
3. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev.
2007 Dec;27(8):959–85.
4. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price:
the cost of mental health care in England to 2026. London: King's Fund;
2008.
5. Bower P, Gilbody S. Stepped care in psychological therapies: access,
effectiveness and efficiency. Br J Psychiatry. 2005;186(1):11–7.
6. National Institute of Health and Care Excellence (NICE). Common Mental
Health Disorders. London: NICE; 2011.
7. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for
depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci.
2008 Sep 11;9(10):788–96.
8. Paykel ES. Partial remission, residual symptoms, and relapse in depression.
Dialogues Clin Neurosci. 2008;10(4):431–7.
9. Cahill J, Barkham M, Hardy G, Rees A, Shapiro DA, Stiles WB, et al. Outcomes
of patients completing and not completing cognitive therapy for
depression. Br J Clin Psychol. 2003 Jun;42(Pt 2):133–43.
10. Radhakrishnan M, Hammond G, Jones PB, Watson A, McMillan-Shields F, Lafortune
L. Cost of improving access to psychological therapies (IAPT) programme: an
analysis of cost of session, treatment and recovery in selected primary care trusts in
the East of England region. Behav Res Ther. 2013 Jan;51(1):37–45.
11. Waller R, Gilbody S. Barriers to the uptake of computerized cognitive
behavioural therapy: a systematic review of the quantitative and qualitative
evidence. Psychol Med. 2009 May 1;39(5):705–12.
12. Gu J, Strauss C, Bond R, Cavanagh K. How do mindfulness-based cognitive
therapy and mindfulness-based stress reduction improve mental health and
wellbeing? a systematic review and meta-analysis of mediation studies. Clin
Psychol Rev. 2015 Jan;37:1–12.
13. Nolen-Hoeksema S, Wisco BE, Lyubomirsky S. Rethinking rumination.
Perspect Psychol Sci. 2008 Sep;3(5):400–24.
14. Teasdale JD. Metacognition, mindfulness and the modification of mood
disorders. Clin Psychol Psychother. 1999 May;6(2):146–55.
15. National Institute of Health and Care Excellence (NICE). Depression: the
treatment and management of depression in adults (update). London: NICE;
2009.
16. Kuyken W, Warren FC, Taylor RS, Whalley B, Crane C, Bondolfi G, et al.
Efficacy of mindfulness-based cognitive therapy in prevention of depressive
relapse. JAMA Psychiatry. 2016 Jun 1;73(6):565.
17. Strauss C, Cavanagh K, Oliver A, Pettman D. Mindfulness-based interventions
for people diagnosed with a current episode of an anxiety or depressive
disorder: a meta-analysis of randomised controlled trials. PLoS One. 2014
Apr 24;9(4):e96110.
18. Cavanagh K, Strauss C, Forder L, Jones F. Can mindfulness and acceptance
be learnt by self-help? A systematic review and meta-analysis of
mindfulness and acceptance-based self-help interventions. Clin Psychol Rev.
2014 Mar;34(2):118–29.
19. Elliott R, Slatick E, Urman M. Qualitative change process research on
psychotherapy: alternative strategies. In: Frommer J, Rennie DL, editors.
Qualitative psychotherapy research: methods and methodology. Lengerich:
Pabst Science; 2001. p. 69–111.
20. Bower P, Kontopantelis E, Sutton A, Kendrick T, Richards DA, Gilbody S, et al.
Influence of initial severity of depression on effectiveness of low intensity
interventions: meta-analysis of individual patient data. Br Med J. 2013;
540(February):1–11.
21. Boggs JM, Beck A, Felder JN, Dimidjian S, Metcalf CA, Segal ZV. Web-based
intervention in mindfulness meditation for reducing residual depressive
symptoms and relapse prophylaxis: a qualitative study. J Med Internet Res.
2014 Jan;16(3):e87.
22. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the
community: a standardized assessment for use by lay interviewers. Psychol
Med. 2009 Jul 9;22(02):465.
23. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001 Sep;16(9):606–13.
24. Evans M, Kessler D, Lewis G, Peters TJ, Sharp D. Assessing mental health in
primary care research using standardized scales: can it be carried out over
the telephone? Psychol Med. 2004 Jan;34(1):S0033291703008055.
25. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing
generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;
166(10):1092–7.
26. NHS Health Scotland and University of Warwick and University of Edinburgh.
Short Warwick-Edinburgh Mental Well-Being Scale. Edinburgh: NHS Health
Scotland and University of Warwick and University of Edinburgh; 2007.
27. Stewart-Brown S, Platt S, Tennant A, Maheswaran H, Parkinson J, Weich S,
et al. The Warwick-Edinburgh Mental Well-being Scale: a valid and reliable
tool for measuring mental well-being in diverse populations and projects. J
Epidemilogy Community Heal. 2011;65(Suppl 2):A38–9.
28. Mundt JC. The Work and Social Adjustment Scale: a simple measure of
impairment in functioning. Br J Psychiatry. 2002 May 1;180(5):461–4.
29. Gu J, Strauss C, Crane C, Barnhofer T, Karl A, Cavanagh K, et al. Examining the
factor structure of the 39-item and 15-item versions of the five-facet mindfulness
questionnaire before and after mindfulness-based cognitive therapy for people
with recurrent depression. Psychol Assess. 2016 Jul;28(7):791–802.
30. Bower P, Byford S, Sibbald B, Ward E, King M, Lloyd M, et al. Randomised
controlled trial of non-directive counselling, cognitive-behaviour therapy,
and usual general practitioner care for patients with depression. II: cost
effectiveness. BMJ. 2000;321(7273):1389–92.
31. Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, et al.
Mindfulness-based cognitive therapy to prevent relapse in recurrent
depression. J Consult Clin Psychol. 2008;76:966–78.
32. Brooks R. EuroQol: the current state of play. Health Policy. 1996 Jul;37(1):53–72.
33. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al.
Development and preliminary testing of the new five-level version of EQ-5D
(EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727–36.
34. Sealed Envelope Ltd. Sealed Envelope: randomisation and online databases
for clinical trials. Available from: www.sealedenvelope.com.
35. Teasdale JD, Williams JMG, Segal Z. The mindful way workbook: an 8-week
program to free yourself from depression and emotional distress. London:
Guildford Press; 2014.
36. Williams C. Overcoming depression and low mood, 3rd edition: a five areas
approach. London: CRC Press; 2012.
37. Williams C, Wilson P, Morrison J, McMahon A, Andrew W, Allan L, et al.
Guided self-help cognitive behavioural therapy for depression in primary
care: a randomised controlled trial. PLoS One. 2013 Jan;8(1):e52735.
38. Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, et al. Cost
and outcome of behavioural activation versus cognitive behavioural therapy
for depression (COBRA): a randomised, controlled, non-inferiority trial.
Lancet. 2016 Aug 27;388(10047):871–80.
39. Saxon D, Ashley K, Bishop-Edwards L, Connell J, Harrison P, Ohlsen S, et al. A
pragmatic randomised controlled trial assessing the non-inferiority of
counselling for depression versus cognitive-behaviour therapy for patients in
primary care meeting a diagnosis of moderate or severe depression
(PRaCTICED): study protocol for a randomised controlled trial. Trials. 2017;18:93.
40. National Institute of Health and Care Excellence (NICE). Guide to the
methods of technology appraisal. London: NICE; 2013.
41. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW.
Methods for the economic evaluation of health care programmes. Oxford:
Oxford University Press; 2015.
42. Thompson SG, Barber JA. How should cost data in pragmatic randomised
trials be analysed? Br Med J. 2000;320:1197–200.
43. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based
cost-effectiveness analysis: the importance of controlling for baseline utility.
Health Econ. 2005 May;14(5):487–96.
44. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis.
Health Econ. 1999 May;8(3):257–61.
45. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br. J.
Psychiatry. 2005;187:106–8.
46. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)
uses of baseline data in clinical trials. Lancet. 2000 Mar 25;355(9209):1064–9.
47. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006 Jan;3(2):77–101.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Strauss et al. Trials          (2020) 21:374 Page 10 of 10
